Introduction
Zimmer Biomet (ZBH) can still be easy to dismiss as a steady but slow orthopedic-implants company tied mostly to hips and knees. The latest quarter suggests the business is broader than that. The company is still anchored by reconstructive orthopedics, but the more useful investor lens now includes extremities, trauma, enabling technology, robotics, and a procedure mix that can support steadier growth and margins than the old label implies.
In the first quarter of 2026, Zimmer Biomet reported net sales of $2.09 billion, up 9.3% on a reported basis, 6.8% in constant currency, and 2.9% on an organic constant-currency basis. Diluted earnings per share rose 34.1% to $1.22, while adjusted diluted earnings per share increased 15.5% to $2.09. Adjusted operating profit margin improved to 27.3% from 26.2% a year earlier, and first-quarter free cash flow reached $245.9 million on operating cash flow of $359.4 million.
Segment Performance
Those numbers matter, but the composition matters more. Knees remained the largest category at $828.6 million in first-quarter sales, while hips contributed $524.1 million. If that were the whole story, the mature-implant framing would still fit. But the Sports Medicine, Extremities, Trauma, Craniomaxillofacial and Thoracic category, or S.E.T., generated $562.2 million and grew 19.5% as reported, while Technology & Data, Bone Cement and Surgical contributed another $171.8 million and grew 14.6%. That mix shows the company is drawing growth from more than just replacement-volume trends in large joints.
The quality of that growth still needs careful reading. Zimmer Biomet said the Paragon 28 acquisition added 3.9 percentage points to first-quarter net sales growth, while foreign exchange contributed another 2.5 points (Form 10-Q for the quarter ended March 31, 2026). The company also noted opportunistic end-of-quarter customer purchases and timing benefits from ROSA Robot and bone cement sales. So this was not a perfectly clean read-through quarter. Still, even after stripping away some of that help, the result supports the idea that the portfolio is broader and more active than a plain “hips and knees” thesis suggests.
That matters because orthopedics is increasingly about procedure ecosystems, not just standalone implants. Zimmer Biomet’s annual filing describes a portfolio spanning knee and hip systems, sports medicine, trauma, craniomaxillofacial products, bone cement, surgical tools, and integrated digital and robotic technologies (Zimmer Biomet Form 10-K for the year ended December 31, 2025). ROSA is part of that push. The company uses ROSA in knee and hip procedures, and management highlighted the full commercial launch of ROSA Knee with OptimiZe during the quarter (Zimmer Biomet first quarter 2026 earnings release). It also pointed to Monogram’s surgeon-guided autonomous knee technology as a future development path and to new implant introductions such as the G7 Acetabular System.
This is the deeper strategic point: robotics and enabling technology can make the core implant business stickier. If surgeons, hospitals, and care systems increasingly choose platforms rather than isolated devices, then the value shifts toward workflow, data, planning, and procedural integration. That does not turn Zimmer Biomet into a software company, but it does mean a larger share of its competitive moat can come from the surrounding ecosystem instead of from implant sales alone.
Capital Deployment
Capital deployment supports that thesis as well. The company repurchased $250 million of stock in the first quarter and ended March with $424.2 million of cash and cash equivalents (Zimmer Biomet first quarter 2026 earnings release; Form 10-Q for the quarter ended March 31, 2026). Long-term debt stood at $6.30 billion, with another $1.18 billion classified as current portion of long-term debt, so this is not a debt-light story (Form 10-Q for the quarter ended March 31, 2026). But Zimmer Biomet also said in its 10-K that it had $1.0 billion available under a 364-day revolving credit agreement and $1.5 billion under a five-year revolver at year-end 2025, which gives it liquidity flexibility as it integrates acquisitions and funds product development (Zimmer Biomet Form 10-K for the year ended December 31, 2025).
The main investor risk is execution quality. Organic constant-currency growth of 2.9% is respectable, but it is not explosive, and some of the first-quarter upside came from timing and acquisition help rather than pure underlying acceleration. If robotics, extremities, and data-enabled products do not translate into cleaner procedure pull-through, the company could still revert to being valued like a slower orthopedic manufacturer.
For now, though, the portfolio looks more dynamic than that label allows. ZBH still depends on joint reconstruction, but it is increasingly building a broader orthopedic procedure platform around it.
Key Signals for Investors
First-quarter results showed that S.E.T. and technology-linked categories are becoming more meaningful growth contributors alongside knees and hips, which supports the broader procedure-mix thesis (Zimmer Biomet first quarter 2026 earnings release).
ROSA, Monogram, and newer implant launches matter because they can deepen surgeon and hospital workflow attachment beyond the underlying implant sale (Zimmer Biomet first quarter 2026 earnings release; Form 10-K for the year ended December 31, 2025).
Investors should keep watching organic constant-currency growth rather than only reported growth, because acquisition and timing benefits can otherwise make the underlying momentum look stronger than it really is (Form 10-Q for the quarter ended March 31, 2026).
